Please select a Capability in order to start your service request.
Each year, about 1.8 million people die from tuberculosis (TB), which is a curable disease. Although there are no simple solutions to the challenges TB brings to developing nations, BD Global Health deploys a strategic combination of resources and technologies aimed at making a positive and sustainable impact.
Rapid culture and drug susceptibility testing is more important than ever in the face of increasing multidrug-resistant TB (MDR-TB) and even extensively drug-resistant TB (XDR-TB). The BD TB liquid-culture method, the BD MGIT™ system, provides diagnostic results much sooner than traditional culture methods, which can take as long as 40 to 50 days to yield a result.
To make high-quality TB diagnosis accessible, especially to HIV-positive patients, BD has an agreement with the Foundation for Innovative New Diagnostics (FIND) to offer access pricing in high-need, low-resource settings. This collaboration established demonstration sites in Africa, Eastern Europe, Brazil and Asia to introduce advanced culture technology at the district hospital level.
In 2014, BD began collaboration with the U.S. Agency for International Development (USAID) Indonesia to support the establishment and thereby strengthen Indonesia's national reference laboratory systems in an ongoing effort to prevent and control infectious disease outbreaks globally. Modeled after the BD-PEPFAR Labs for Life program, the partnership supported Indonesia's National Tuberculosis Program (NTP) with the aim to improve and expand quality-assured laboratory services. In particular, the collaboration emphasized the early detection and confirmation of TB cases, as well as monitoring and treatment services. The partnership ended in December 2016, with the following outcomes: